Linked Life Data

11391836

Source:http://linkedlifedata.com/resource/pubmed/id/11391836

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-6-5
pubmed:abstractText
The efficacy and safety of recombinant interferon alfa-2a (rIFN) was evaluated in 26 adult Nigerian patients with chronic hepatitis B infection. Male and female patients with serological evidence of HBV infection (HBsAg and/or HBeAg positive patients) and abnormal liver histology were monitored for six months to confirm chronicity. At the end of the six months screening period eligible patient were enrolled into the study and treated with rIFN 4.5 MIU given three times a week for 6 months. Efficacy was assessed primarily by loss of HBV-DNA and/or HBeAg from serum and secondarily by loss of HBsAg and normalization of the liver histology. Safety was assessed by monitoring the leukocyte and platelet count over the treatment period whilst tolerability was assessed by recording the occurrence of adverse events (adverse drug reaction and intercurrent illness). At the end of therapy the response rate with respect to loss of HBV-DNA was 67% and 100% for HBeAg (i.e. for the six patients who were HBeAg positive at baseline). There was loss of HBsAg in 22.2% of the patients. A significant reduction in inflammation and necrosis scores was found among the 10 patients who had both baseline and term biopsies. The frequency of occurrence of adverse events was 53.8% and the laboratory safety parameters were not significantly affected by therapy (p > 0.05). 19.2% of the enrolled patients were withdrawn from the study prematurely. These results demonstrate that rIFN is effective in the management of CHB infection even in Nigerians. The high success rate associated with HBcAg clearance is particularly noteworthy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0189-160X
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
259-64
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:11391836-Adult, pubmed-meshheading:11391836-Alanine Transaminase, pubmed-meshheading:11391836-Antiviral Agents, pubmed-meshheading:11391836-Biopsy, pubmed-meshheading:11391836-Drug Monitoring, pubmed-meshheading:11391836-Female, pubmed-meshheading:11391836-Hepatitis B, Chronic, pubmed-meshheading:11391836-Hepatitis B Surface Antigens, pubmed-meshheading:11391836-Hepatitis B e Antigens, pubmed-meshheading:11391836-Humans, pubmed-meshheading:11391836-Interferon-alpha, pubmed-meshheading:11391836-Leukocyte Count, pubmed-meshheading:11391836-Male, pubmed-meshheading:11391836-Middle Aged, pubmed-meshheading:11391836-Nigeria, pubmed-meshheading:11391836-Platelet Count, pubmed-meshheading:11391836-Prospective Studies, pubmed-meshheading:11391836-Recombinant Proteins, pubmed-meshheading:11391836-Safety, pubmed-meshheading:11391836-Treatment Outcome
pubmed:articleTitle
Interferon alfa-2a (Roferon-A) in the management of chronic hepatitis B infection: results of an open prospective study in Nigerian patients.
pubmed:affiliation
Department of Medicine, Univ. College Hospital, Ibadan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't